Enlivex Therapeutics Ltd. - Ordinary Shares (ENLV)
Frequently Asked Questions About Enlivex Therapeutics Ltd. - Ordinary Shares (ENLV)
Has Enlivex received any funding?
Yes, Enlivex Therapeutics has secured funding through various rounds of investment, including public offerings and private placements. These funds are primarily allocated towards advancing clinical trials and further developing their proprietary technology and therapies.
How can investors stay updated about Enlivex?
Investors can stay updated on Enlivex Therapeutics through various channels, including the company's official website, which provides news releases and updates on clinical advancements. Additionally, Enlivex engages with investors through earnings calls and presentations at biotech conferences, where management discusses company progress.
How does Enlivex address regulatory compliance?
Enlivex Therapeutics is committed to adhering to strict regulatory compliance as it progresses through drug development and clinical trials. The company works closely with regulatory bodies such as the U.S. FDA and equivalent agencies in other regions, ensuring that its processes meet necessary safety and efficacy standards.
How does Enlivex intend to scale its operations?
Enlivex plans to scale its operations through strategic partnerships, further investment in R&D, and expanding clinical trial phases. As they advance their therapies through successful trials, the company intends to broaden its market reach and enhance production capabilities to meet potential demand.
Is Enlivex listed on any stock exchanges?
Yes, Enlivex Therapeutics Ltd. is listed on the Nasdaq Global Market under the ticker symbol 'ENLV'. The public listing provides the company with access to capital markets to support its clinical development and operational activities.
What are the potential applications for Apocept?
The potential applications for Apocept are broad, including treatment for sepsis, severe asthma attacks, and other conditions characterized by immune overreaction or failure. Enlivex is actively exploring various therapeutic indications where immune modulation is essential for improving patient outcomes.
What are the risks associated with investing in Enlivex?
Investing in Enlivex carries typical biotech risks, such as the inherent uncertainty of clinical trials and product development. Additionally, the company may face financial volatility and operational challenges. Investors should consider these factors when evaluating an investment in Enlivex.
What differentiates Enlivex from other biotech companies?
Enlivex differentiates itself through its unique approach to immunotherapy, particularly with its proprietary cell therapy platform that focuses on restoring immune balance. This innovative strategy, combined with a solid team of experts in the field, positions the company uniquely within the biotech landscape.
What does Enlivex Therapeutics Ltd. do?
Enlivex Therapeutics Ltd. is a clinical-stage biotechnology company focused on developing immunotherapy treatments. Its primary goal is to leverage its innovative cell therapy platform, particularly its Apocept product, to combat life-threatening diseases caused by dysregulated immune responses. This includes severe conditions such as sepsis and acute respiratory distress syndrome.
What is Apocept?
Apocept is Enlivex Therapeutics' leading product candidate, a novel cell therapy designed to modulate the immune system. Its primary mechanism involves restoring a balanced immune response, which can be crucial in treating a variety of conditions characterized by immune dysregulation, including severe infections and allergic responses.
What is Enlivex's mission?
The mission of Enlivex Therapeutics is to develop transformative immunotherapy treatments that significantly improve the quality of life for patients suffering from acute and critical conditions. The company is dedicated to pioneering innovative therapies that address immune system failures in a targeted manner.
What is the significance of Enlivex's research?
Enlivex's research is significant because it aims to tackle complex health issues related to immune system failures, which frequently lead to high mortality rates in critical care. By innovating in this area, Enlivex seeks to provide new hope and effective solutions for patients enduring life-threatening conditions.
What is the target market for Enlivex products?
Enlivex Therapeutics targets markets requiring advanced treatments for severe immune dysregulation, particularly in critical care settings. Their products aim to address unmet medical needs in sepsis, organ failure, and autoimmune disorders, which represent significant opportunities within the global healthcare market.
What partnerships or collaborations does Enlivex have?
Enlivex has established collaborations with various academic institutions and industry partners to enhance its research capabilities and clinical program execution. These partnerships facilitate access to cutting-edge technologies and expertise that are crucial for advancing their product candidates.
What stage of development is Apocept currently in?
Apocept is currently in the clinical trials phase, where it is being evaluated for safety and efficacy in patients with severe immune-related conditions. The company is progressing through various phases of clinical studies, with results critical to determining the path forward for regulatory approval.
When was Enlivex Therapeutics founded?
Enlivex Therapeutics was founded in 2018, rising from a research initiative aimed at developing advanced immunotherapeutic strategies. The founding team consisted of scientists and entrepreneurs with extensive backgrounds in biotech and pharmaceutical R&D, driving the company forward since its inception.
Where is Enlivex Therapeutics located?
Enlivex Therapeutics is based in Israel, where it conducts much of its research and development. The company aims to expand its operations and collaborations globally, focusing on improving patient outcomes through innovative therapies.
Who are the key personnel at Enlivex?
Enlivex Therapeutics boasts a team of experienced leaders in biotech and pharmaceuticals, including its CEO, who plays a pivotal role in guiding the company’s strategic direction. The team also includes experts in immunology, regulatory affairs, and clinical development, fostering a strong foundation for R&D efforts.
What is the current price of Enlivex Therapeutics Ltd. - Ordinary Shares?
The current price of Enlivex Therapeutics Ltd. - Ordinary Shares is 0.8924
When was Enlivex Therapeutics Ltd. - Ordinary Shares last traded?
The last trade of Enlivex Therapeutics Ltd. - Ordinary Shares was at 2:37 pm EDT on April 4th, 2025
What is the market capitalization of Enlivex Therapeutics Ltd. - Ordinary Shares?
The market capitalization of Enlivex Therapeutics Ltd. - Ordinary Shares is 16.34M
How many shares of Enlivex Therapeutics Ltd. - Ordinary Shares are outstanding?
Enlivex Therapeutics Ltd. - Ordinary Shares has 18.31M shares outstanding.